FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Dillione Janet
2. Issuer Name and Ticker or Trading Symbol

CorMedix Inc. [ CRMD ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O CORMEDIX INC., 300 CONNELL DRIVE, SUITE 4200
3. Date of Earliest Transaction (MM/DD/YYYY)

2/22/2022
(Street)

BERKELEY HEIGHTS, NJ 07922
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock         53473 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy Common Stock) $4.03 2/22/2022  A   20000     (9)2/22/2032 Common Stock 20000 $0 20000 D  
Stock Option (Right to Buy Common Stock) $8.32            (1)1/11/2031 Common Stock 30000  30000 D  
Phantom Stock $0            (2) (2)Common Stock 3583  3583 D  
Phantom Stock $0            (2) (2)Common Stock 4770  4770 D  
Phantom Stock $0            (2) (2)Common Stock 5253  5253 D  
Stock Option (Right to Buy Common Stock) $5.63            (3)2/25/2030 Common Stock 15000  15000 D  
Phantom Stock $0            (2) (2)Common Stock 1706  1706 D  
Phantom Stock $0            (2) (2)Common Stock 2099  2099 D  
Phantom Stock $0            (2) (2)Common Stock 945  945 D  
Phantom Stock $0            (2) (2)Common Stock 1126  1126 D  
Phantom Stock $0            (2) (2)Common Stock 843  843 D  
Stock Option (Right to Buy Common Stock) $8.3            (4)1/10/2029 Common Stock 15000  15000 D  
Phantom Stock $0            (2) (2)Common Stock 1328  1328 D  
Phantom Stock $0            (2) (2)Common Stock 2728  2728 D  
Phantom Stock $0            (2) (2)Common Stock 7500  7500 D  
Stock Option (Right to Buy Common Stock) $2.85            (5)2/16/2028 Common Stock 8000  8000 D  
Phantom Stock $0            (2) (2)Common Stock 2679  2679 D  
Phantom Stock $0            (2) (2)Common Stock 3125  3125 D  
Phantom Stock $0            (2) (2)Common Stock 4167  4167 D  
Stock Option (Right to Buy Common Stock) $11.2            (6)2/21/2027 Common Stock 8000  8000 D  
Phantom Stock $0            (2) (2)Common Stock 695  695 D  
Phantom Stock $0            (2) (2)Common Stock 829  829 D  
Stock Option (Right to Buy Common Stock) $15.15            (7)8/11/2025 Common Stock 10000  10000 D  
Phantom Stock $0            (2) (2)Common Stock 283  283 D  
Stock Option (Right to Buy Common Stock) $9.55            (8)2/21/2026 Common Stock 19000  19000 D  
Phantom Stock $0            (2) (2)Common Stock 767  767 D  
Phantom Stock $0            (2) (2)Common Stock 554  554 D  
Phantom Stock $0            (2) (2)Common Stock 867  867 D  
Phantom Stock $0            (2) (2)Common Stock 3062  3062 D  

Explanation of Responses:
(1) These options were granted on 1/11/2021. These options are fully vested.
(2) Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director.
(3) These options were granted on 02/25/2020. These options are fully vested.
(4) These options were granted on 01/10/2019. These options are fully vested.
(5) These options were granted on 02/16/2018. These options are fully vested.
(6) These options were granted on 02/21/2017. These options are fully vested.
(7) These options were granted on 08/12/2015. These options are fully vested.
(8) These options were granted on 02/21/2016. These options are fully vested.
(9) These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board.

Remarks:
The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Dillione Janet
C/O CORMEDIX INC., 300 CONNELL DRIVE
SUITE 4200
BERKELEY HEIGHTS, NJ 07922
X



Signatures
/s/ Janet Dillione2/22/2022
**Signature of Reporting PersonDate


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
CorMedix (AMEX:CRMD)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse CorMedix
CorMedix (AMEX:CRMD)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse CorMedix